Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

AIMS: Branebrutinib (BMS‐986195) is a potent, highly selective, oral, small‐molecule, covalent inhibitor of Bruton's tyrosine kinase (BTK). This study evaluated safety, pharmacokinetics and pharmacodynamics of branebrutinib in healthy participants. METHODS: This double‐blind, placebo‐controlled...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Clin Pharmacol
Main Authors: Catlett, Ian M., Nowak, Miroslawa, Kundu, Sudeep, Zheng, Naiyu, Liu, Ang, He, Bing, Girgis, Ihab G., Grasela, Dennis M.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444767/
https://ncbi.nlm.nih.gov/pubmed/32198939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14290
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker